Stockscreener 앱 받기
1.39
0.72%
0.01
시간 외 거래:
1.40
0.01
+0.72%
Vor Biopharma Inc 주식(VOR)의 최신 뉴스
SEC Form 424B3 filed by Vor Biopharma Inc. - Quantisnow
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36 - MarketBeat
FOXO Technologies Announces Special Shareholders Meeting - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Arcadia Biosciences (NASDAQ:RKDA) Now Covered by Analysts at StockNews.com - Defense World
AngioDynamics (ANGO) to Host NanoKnife Investor Event - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Allurion Technologies (NYSE: ALUR) Enters into Omnibus Amendment to Amend Note Purchase Agreement and RIFAsOn January 7, 2025, Allurion Technologies, Inc. (NYSE: ALUR) and Allurion OpCo entered into an Omnibus Amendment with various entitie - Defense World
Vor Biopharma Strengthens Board with New Appointment - TipRanks
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - GlobeNewswire Inc.
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - Yahoo Finance
Vor biopharma sees significant stock acquisition by Reid Hoffman - Investing.com South Africa
Vor Biopharma's chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Australia
Vor Biopharma's chief medical officer sells shares worth $12,917 - Investing.com India
Vor Biopharma’s chief medical officer sells shares worth $12,917 By Investing.com - Investing.com Nigeria
Vor Biopharma Inc. (NYSE:VOR) Insider Sells $12,917.50 in Stock - MarketBeat
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus.com
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com India
Vor Biopharma’s SWOT analysis: promising AML therapy stock faces pivotal year - Investing.com Nigeria
Vor Biopharma's SWOT analysis: promising AML therapy stock faces pivotal year By Investing.com - Investing.com South Africa
Vor Biopharma Inc. announced that it has received $55.55 million in funding from RA Capital Management, L.P. - Marketscreener.com
Vor Bio Announces $55.6 Million Private Placement - Marketscreener.com
Vor Biopharma Inc. Announces $55.6 Million Private Placement - Defense World
Vor Biopharma Secures $55.6M for Cancer Therapy Trials - Yahoo Finance
Vor Biopharma Inc. announced that it expects to receive $55.55 million in funding - Marketscreener.com
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Ne - GuruFocus.com
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% - Yahoo Finance UK
What's Going On With Vor Biopharma Shares Friday? - Benzinga
Vor BioPharma stocks surge 33% after private placement By Investing.com - Investing.com Canada
Vor Bio announces $55.6M private placement, shares soar - Seeking Alpha
Vor Biopharma : Bio Announces $55.6 Million Private Placement Form 8 K - Marketscreener.com
Vor Bio Secures $55.6M Investment Led by Reid Hoffman, Extends Runway for Key 2025 Trial Results - StockTitan
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Simply Wall St
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Vor Biopharma's SWOT analysis: stock shows promise amid AML treatment advances - Investing.com Canada
Vor Biopharma’s (VOR) Buy Rating Reiterated at HC Wainwright - Defense World
Vor Biopharma’s (VOR) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Vor Biopharma’s (VOR) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Vor Biopharma Announces Updated Clinical Data and FDA Feedback – - Defense World
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from Fda Regarding Registrational Trial Design - Marketscreener.com
Vor Biopharma : Bio Corporate Presentation December 2024 - Marketscreener.com
Vor Biopharma Reports Promising Phase 1/2 Study Results - TipRanks
Vor Bio Provides Clinical Update Further Validating - GlobeNewswire
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design - Marketscreener.com
5.49%
0.79%
자본화:
|
볼륨(24시간):